Navigation Links
FDA Advisers Say Avastin Shouldn't Be Used for Breast Cancer
Date:7/21/2010

TUESDAY, July 20 (HealthDay News) -- The cancer drug Avastin should no longer be used as a treatment for breast cancer, a U.S. Food and Drug Administration advisory panel voted Tuesday, saying the drug wasn't benefiting patients.

The 12 to 1 vote represented a setback for Avastin, which is the world's best-selling cancer drug, with sales last year of about $6 billion. Avastin is sold by drug maker Roche's Genentech unit, The New York Times reported.

Earlier Tuesday, the advisory committee said data suggested that at least for breast cancer, the initial data that led to accelerated approval of Avastin in 2008 for breast cancer was not borne out by subsequent studies.

The drug is also approved for lung, colon, kidney and brain cancer, the Associated Press reported.

The 13 experts convened by the FDA voted unanimously that the drug's side effects and risks outweighed benefits when used with conventional chemotherapy.

When the FDA approved Avastin for breast cancer patients in 2008, it was on the condition that Roche provide additional studies supporting evidence that the drug kept the disease from worsening for more than five months.

But two follow-up studies failed to show that same effect, and patients did not gain any survival benefits. But they did experience serious side effects, including fatigue, abnormal white blood cell counts and high blood pressure, the AP reported.

"The study shows there's very little benefit to patients with significant toxicity risks and no clear survival benefit," said Natalie Compagni Portis, the FDA advisory panel's patient representative, the news service reported.

The FDA is not bound to follow the recommendations of its advisory committees, but typically does so.

More information

To learn more about Avastin, visit the U.S. National Library of Medicine.

-- HealthDay staff

SOURCES: U.S. Food and Drug Administration; The New York Times; Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA to Broaden Disclosure on Advisers Conflicts of Interest
2. FDA Advisers Urge Stricter Regulation of Tanning Beds
3. Avastin Largely Safe for Patients With Type of Advanced Lung Cancer
4. Breast cancer cells regulate multiple genes in response to estrogen-like compounds
5. Susan G. Komen awards Case Western Reserve nearly $500,000 to study breast cancer in older women
6. Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer
7. Experts Issue New Guidelines on Breast Cancer Drugs
8. Radiation device allows for targeted breast radiation to control cancer
9. Scientists reprogram triple-negative breast cancer cells to respond to tamoxifen
10. Fish Oil Supplements Linked to Lower Risk of Breast Cancer: Study
11. Mathematical models for breast cancer detection with microwave tomography are cheaper and less risky
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: